Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial

被引：0

作者：

Vaduganathan, M. ^{[1
]}

Sattar, N. ^{[2
]}

Fitchett, D. ^{[3
]}

Ofstad, A. ^{[4
]}

Brueckmann, M. ^{[5
,6
]}

George, J. T. ^{[5
]}

Verma, S. ^{[3
]}

Mattheus, M. ^{[7
]}

Wanner, C. ^{[8
]}

Inzucchi, S. E. ^{[9
]}

Zinman, B. ^{[10
]}

Butler, J. ^{[11
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Univ Glasgow, Glasgow, Lanark, Scotland

[3] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[4] Boehringer Ingelheim KS, Asker, Norway

[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[6] Heidelberg Univ, Mannheim, Germany

[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[8] Univ Hosp Wurzburg, Wurzburg, Germany

[9] Yale Univ, Sch Med, Yale New Haven Hosp, New Haven, CT USA

[10] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada

[11] Univ Mississippi, Jackson, MS 39216 USA

来源：

DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

572

引用

页码：S275 / S275

页数：1

共 50 条

[1] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
Bernard Zinman
Silvio E. Inzucchi
Christoph Wanner
Uwe Hehnke
Jyothis T. George
Odd Erik Johansen
David Fitchett
Diabetologia, 2018, 61 : 1522 - 1527
[2] Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
Vaduganathan, Muthiah
Inzucchi, Silvio E.
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Zinman, Bernard
Butler, Javed
DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2775 - 2784
[3] Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
DIABETES, 2020, 69
[4] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
Verma, Subodh
Mazer, C. David
Bhatt, Deepak L.
Raj, Satish R.
Yan, Andrew T.
Verma, Atul
Ferrannini, Ele
Simons, Gudrun
Lee, Jisoo
Zinman, Bernard
George, Jyothis T.
Fitchett, David
DIABETES CARE, 2019, 42 (03) : E42 - E44
[5] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kaku, Kohei
Lee, Jisoo
Mattheus, Michaela
Kaspers, Stefan
George, Jyothis
Woerle, Hans-Juergen
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
Strivay, M.
Vereecken, G.
Keymeulen, B.
Lamkanfi, F.
CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
[6] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
Zinman, Bernard
Inzucchi, Silvio E.
Wanner, Christoph
Hehnke, Uwe
George, Jyothis T.
Johansen, Odd Erik
Fitchett, David
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
Strivay, M.
Vereecken, G.
Keymeulen, B.
DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
[7] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Fitchett, David
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Hantel, Stefan
Salsali, Afshin
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
[8] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
Fisher, Miles
BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141
[9] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
Sharma, Abhinav
Inzucchi, Silvio E.
Testani, Jeffrey
Ofstad, Anne-Pernille
Fitchett, David
Mattheus, Michaela
Verma, Subodh
Zannad, Faiez
Wanner, Christoph
Kraus, Bettina J.
JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
[10] Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
Coleman, R. L.
Gray, A.
Broedl, U. C.
Fitchett, D.
George, J. T.
Woerle, H. J.
Zinman, B.
Holman, R. R.
DIABETIC MEDICINE, 2017, 34 : 23 - 23

← 1 2 3 4 5 →